RxDoctor Payments DataLook up a doctor →

Raja Taunk, MD

Gastroenterology · Annapolis, MDNPI 1073772976

Payments from drug & device makers

$328,430in general payments, 2019–2025

Across 831 payments — averaging $395.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$199K
  • Johnson & Johnson$50K
  • Phathom Pharmaceuticals, Inc.$23K
  • Takeda Pharmaceuticals U.S.A., Inc.$23K
  • E.r. Squibb & Sons, L.L.C.$15K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$5K
  • plus $14K from 34 others

What the payments were for

  • Consulting fees$28,9439%
  • Speaking & faculty fees$255,71978%
  • Travel & lodging$26,6298%
  • Food & beverage$16,9215%
  • Education$2180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$328,430 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$539,843
Medicare patients
777
Services billed
22,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi On-BodyRisankizumab-Rzaa13$270,499
RinvoqUpadacitinib26$222,450
CreonLipase/Protease/Amylase36$115,591
Humira(Cf) PenAdalimumab16$111,293
LinzessLinaclotide58$42,022
Mesalamine22$17,138
Pantoprazole Sodium467$8,256
SutabSod Sulf/Pot Chloride/Mag Sulf44$6,974
Budesonide EcBudesonide13$5,194
Esomeprazole Magnesium63$4,613
Lubiprostone13$3,320
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates59$3,317
Dexlansoprazole DrDexlansoprazole11$2,916
Ursodiol12$2,397
Famotidine128$2,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Creon, Linzess$198,710$380,063120 claims
Braintree Laboratories, Inc.Sutab$39$6,97444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →